Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01719302 · ClinicalTrials.gov registry record · Phase 1
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
A Phase 1 study of Stage III Adult Soft Tissue Sarcoma, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01719302: Completed Phase 1 study of Stage III Adult Soft Tissue Sarcoma, sponsored by University of Vermont.
NCT01719302 is a Phase 1 study of Stage III Adult Soft Tissue Sarcoma that has completed, run by University of Vermont. The registered enrollment target is 6 participants, below the 59-participant average among 5 other Stage III Adult Soft Tissue Sarcoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01719302, a Phase 1 study of Stage III Adult Soft Tissue Sarcoma, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Chemotherapy treatment with docetaxel and gemcitabine is a standard treatment for patients with soft tissue sarcoma. This study is designed to explore whether the addition of tyrosine kinase inhibitor pazopanib enhances the anticancer effect of the chemotherapy drugs. The Phase I component of this study is designed to determine the maximum tolerated dose of pazopanib when given with docetaxel and gemcitabine. The Phase II component is designed to determine the overall response rate of the combination of docetaxel, gemcitabine and pazopanib prior to surgical resection in patients with soft tissue sarcoma.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Pazopanib
Study Locations (1)
Vermont
- Fletcher Allen Health Care - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
What the finished NCT01719302 record still lists
NCT01719302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 59-participant average among 5 other Stage III Adult Soft Tissue Sarcoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Stage III Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT01719302 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT01719302 about?
NCT01719302 is a clinical study titled "Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma". Chemotherapy treatment with docetaxel and gemcitabine is a standard treatment for patients with soft tissue sarcoma. This study is designed to explore whether the addition of tyrosine kinase inhibitor pazopanib enhances the anticancer effect of the chemotherapy drugs. The Phase I component of this ...
What is the current status of trial NCT01719302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-10. Estimated completion is 2015-04.
What conditions does trial NCT01719302 study?
This clinical trial studies the following conditions: Stage III Adult Soft Tissue Sarcoma.
What interventions are being tested in trial NCT01719302?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01719302?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01719302 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia